CHEK1 Recombinant Monoclonal Antibody

文獻引用 (1) 說明書

中文名稱：

CHEK1重組抗體
貨號：

CSB-RA176809A0HU
規格：

￥1320
圖片：
Western Blot
Positive WB detected in: K562 whole cell lysate, 293T whole cell lysate, MCF-7 whole cell lysate, HepG2 whole cell lysate
All lanes: Chk1 antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 55, 44, 51 kDa
Observed band size: 55 kDa

IHC image of CSB-RA176809A0HU diluted at 1:100 and staining in paraffin-embedded human small intestine tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.

Immunofluorescence staining of Hela Cells with CSB-RA176809A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeated by 0.2% TritonX-100, and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).
其他：

產品詳情
產品評價
引用文獻
相關產品
靶點詳情

產品詳情

產品描述：

本產品為CHEK1重組單克隆抗體（貨號CSB-RA176809A0HU），針對細胞周期檢查點激酶1（CHEK1）設計，該靶標在DNA損傷應答通路中發揮核心作用，通過調控細胞周期停滯和DNA修復機制維持基因組穩定性，其功能異常與腫瘤發生及治療敏感性密切相關。本抗體經ELISA、蛋白質印跡（WB）、免疫組織化學（IHC）和免疫熒光（IF）多平臺驗證，展現出優異的特異性和靈敏度：在WB實驗中可精準識別內源性CHEK1蛋白，推薦稀釋梯度1:500-1:5000；IHC應用下（稀釋比1:50-1:200）可清晰顯示組織切片中靶蛋白的亞細胞定位；IF實驗（稀釋比1:20-1:200）則適用于活細胞或固定細胞的蛋白動態觀察。該產品適用于研究細胞周期調控機制、DNA損傷修復通路及化療藥物作用機理等領域，為探索腫瘤發生發展分子機制及藥物靶點篩選提供高可靠性工具，嚴格限于科研用途。
Uniprot No.：

O14757
基因名：

CHEK1
別名：

Serine/threonine-protein kinase Chk1 (EC 2.7.11.1) (CHK1 checkpoint homolog) (Cell cycle checkpoint kinase) (Checkpoint kinase-1), CHEK1, CHK1
反應種屬：

Human
免疫原：

A synthesized peptide derived from human Chk1
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

2F2
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:200
IF	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

引用文獻

Enhanced Anti-Cancer Effects of Conditioned Medium from Hypoxic Human Adult Dermal Fibroblasts on Cervical Cancer Cells KH Han,International journal of molecular sciences,2022

產品評價

靶點詳情

功能：

Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA. May also negatively regulate cell cycle progression during unperturbed cell cycles. This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome. Recognizes the substrate consensus sequence Endogenous repressor of isoform 1, interacts with, and antagonizes CHK1 to promote the S to G2/M phase transition.
基因功能參考文獻：
1. These results indicate that, under stressful conditions, maintained mTORC1 signaling in cancer cells promotes survival by suppressing endogenous DNA damage, and may control cell fate through the regulation of CHK1. PMID: 28484242
2. Chk1 and 14-3-3 proteins cooperate to inactivate the transcriptional repressor functions of atypical E2F proteins. This mechanism might be of particular importance to cancer cells, since they are exposed frequently to DNA-damaging therapeutic reagents. PMID: 29363506
3. Study provides evidence that expression of CHEK1 protein is high in breast tumors arising in Nigerian women and is associated with aggressive cancer phenotypes and is a prognostic marker. PMID: 29075961
4. This study reports the crystal structure of the human Chk1 putative kinase-associated 1 (KA1) domain, demonstrating striking structural homology with other sequentially diverse KA1 domains. Separately purified Chk1 kinase and KA1 domains are intimately associated in solution, which results in inhibition of Chk1 kinase activity. PMID: 28972186
5. The nuclear transcription factor Y subunit beta (NFYB)-E2F transcription factor 1 (E2F1) pathway displays a crucial role in the chemoresistance ofoxaliplatin-resistant colorectal cancer (OR-CRC) by inducing the expression and activation of checkpoint kinase 1 (CHK1), suggesting a possible therapeutic target for oxaliplatin resistance in CRC. PMID: 29203250
6. Blocking apoptosis alone is insufficient to allow the subsequent outgrowth of primary B cells lacking CHK1 in vivo or B lymphoma lines in vitro, as these cells trigger p53- dependent cell cycle arrest in response to the accumulating DNA damage. PMID: 29167438
7. Chk1 and Chk2 are significantly expressed in human sperm. In case of sperm DNA damage, up-regulated Chk1 expression may enhance sperm apoptosis and lead to asthenospermia, while increased Chk2 expression may inhibit spermatogenesis and result in oligospermia. PMID: 29658237
8. CHK1 and CHK2 and their activated forms are frequently expressed in HGSC effusions, with higher expression following exposure to chemotherapy, and their expression is related to survival. PMID: 29804637
9. expression of AURKA and CHEK1 was linked with detrimental outcome in patients. Our data describe a synthetic lethality interaction between CHEK1 and AURKA inhibitors with potential translation to the clinical setting PMID: 28847989
10. Expression levels of phosphorylated cdc25A (p-cdc25A) and phosphorylated Chk1 (p-Chk1), belonging to the ATR pathway, were decreased by treatment with Dclk1 inhibitor LRRK2-IN-1 (LRRK), indicating Dclk1 involvement in the ATR pathway PMID: 29048622
11. these data demonstrate that prexasertib is a specific inhibitor of CHK1 in neuroblastoma and leads to DNA damage and cell death in preclinical models of this devastating pediatric malignancy. PMID: 28270495
12. results show that HGF was involved in regulating Chk1 phosphorylation, and further demonstrate that AKT activity was responsible for this HGF-induced Chk1 phosphorylation. PMID: 28573382
13. Chk1 was linked to DNA damage response bypass by suppressing JNK activation following oxidative stress, promoting cell cycle progression despite DNA damage. PMID: 28751935
14. inhibition of Chk1 can potentiate activity of nucleoside analogs in TP53-mutated B-lymphoid cells PMID: 27556692
15. Data show that protein phosphatase-1 alpha (PP1alpha) is required to maintain checkpoint kinase 1 (CHK1) in a dephosphorylated state and for the accelerated replication fork progression in Spi1/PU.1 transcription factor-overexpressing cells. PMID: 28415748
16. Chk1 inhibition with GDC-0425 in combination with gemcitabine was tolerated with manageable bone marrow suppression. The observed preliminary clinical activity warrants further investigation of this chemopotentiation strategy PMID: 27815358
17. Data show that the checkpoint kinase 1/2 (Chk1/Chk2) inhibitor prexasertib (LY2606368) inhibits cell viability in B-/T-ALL cell lines. PMID: 27438145
18. we demonstrate that CHK1 mRNA is overexpressed in two independent cohorts of medulloblastoma patient samples in comparison to normal cerebellum PMID: 27449089
19. results suggest a Chk1-OGT-vimentin pathway that regulates the intermediate filament network during cytokinesis PMID: 29021254
20. CHEK1-mediated DNA damage checkpoint has a role in the ESR2-NCF1-ROS pathway sensitization of esophageal cancer cells to 5-fluorouracil-induced cell death PMID: 27310928
21. monitoring CHEK1 expression could be used both as a predictor of outcome and as a marker to select AML patients for CHK1 inhibitor treatments. PMID: 27625304
22. PLAUR to be essential for activation of Checkpoint kinase 1 (CHK1); maintenance of cell cycle arrest after DNA damage in a TP53-dependent manner; expression, nuclear import and recruitment to DNA-damage foci of RAD51 recombinase, the principal protein involved in the homologous recombination repair pathway. PMID: 27685627
23. Results unveil a new aspect of PERK function and previously unknown roles for Claspin and Chk1 as negative regulators of DNA replication in the absence of genotoxic stress. PMID: 27375025
24. The findings reveal ATXN3 to be a novel deubiquitinase of Chk1, providing a new mechanism of Chk1 stabilization in genome integrity maintenance. PMID: 28180282
25. These findings demonstrate an unsuspected requirement for a balanced nucleotide pool for optimal Chk1 activation both in unchallenged cells and in response to genotoxic stress. PMID: 27383768
26. CHK1 overexpression is associated with T-cell and Hodgkin Lymphoma. PMID: 26988986
27. Checkpoint kinase 1 and 2 signaling is important for apoptin regulation. PMID: 27512067
28. Genetic variants of the CHEK1 gene are significantly related to overall survival and disease-free survival of esophageal squamous cell carcinoma patients. PMID: 27924519
29. Role of the CHK1-RAD51 signaling pathway in osteosarcoma cells. PMID: 28000895
30. High CHK1 expression is associated with increased radioresistance of non-small cell lung cancer. PMID: 27553023
31. CHEK1 loss-of-function mutations have not been found in human tumors, and transgenic expression of Chek1 in mice promotes oncogene-induced transformation. [review] PMID: 26527132
32. persistence of CHK1 levels in response to DNA damage in p53-deficient cancer cells, leads to CHK1-mediated activation of NF-kappaB and induction of NF-kappaB-regulated genes in cells and in associated tumor-derived microvesicles, both of which are abrogated by loss or inhibition of CHK1. PMID: 26921248
33. Chk1's expression is controlled by p53 and RB/E2F1 at the transcriptional level. PMID: 26867682
34. High CHK1 expression correlates with urinary bladder cancer. PMID: 26657501
35. This study shows that Chk1 indeed maintains a closed conformation in the absence of DNA damage through an intramolecular interaction between a region (residues 31-87) at the N-terminal kinase domain and the distal C terminus. A highly conserved Leu-449 at the C terminus is important for this intramolecular interaction. PMID: 27129240
36. Avoiding damage formation through invalidation of Mus81-Eme2 and Mre11, or preventing damage signaling by turning off the ATM pathway, suppresses the replication phenotypes of Chk1-deficient cells. PMID: 26804904
37. Chk1 is a predictive biomarker of radiotherapy resistance and early local recurrence. PMID: 26459098
38. A new pathway of proliferation restriction for tetraploid untransformed cells that seems to be specific for loss of adhesion dependent cytokinesis failure involves Chk1 and p53 activation during G2. PMID: 26693937
39. Human induced pluripotent stem cells fail to activate CHK1 when exposed to DNA replication inhibitors and commit to apoptosis instead. PMID: 26810087
40. Isolate/characterize mantle cell lymphoma cell line resistance to Chk1 inhibitor PF-00477736. PMID: 26439697
41. Results support the inhibition of checkpoint kinase 1 (Chk1) as a new therapeutic strategy in acute lymphoblastic leukemia. PMID: 26542114
42. these results demonstrate a positive feedback loop involving Rad9A-dependend activation of Chk1. PMID: 26658951
43. DNA damage induces Chk1 phosphorylation on chromatin followed by releasing phospho-Chk1 from the chromatin into soluble nucleus and the cytoplasm where Chk1 activates the cell cycle checkpoints; and Chk1 is degraded and checkpoint signaling is terminated. PMID: 26296656
44. nasopharyngeal carcinoma cells depend on CHK1 and WEE1 activity for growth PMID: 26025928
45. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis PMID: 25653093
46. Report strong synergism observed by combining Chk1 and Wee1 inhibitors in preclinical models of mantle cell lymphoma. PMID: 25428911
47. mutations targeting the putative Chk1 KA1 domain confer constitutive biological activity by circumventing the need for ATR-mediated positive regulatory phosphorylation. PMID: 26039276
48. CHEK1 was a direct target of miR-195, which decreased CHEK1 expression in lung cancer cells. High expression of CHEK1 in lung tumors was associated with poor overall survival. PMID: 25840419
49. Our findings suggest that the addition of CHEK1 inhibitor increases the response of ovarian cancer cells to TPT. Furthermore, reduced dosages of both drugs achieved maximal cytotoxic effects by combining TPT with CHEK1 inhibitor. PMID: 25884494
50. these results suggest that breast cancer cells may rely on mTORC2-Chk1 pathway for survival PMID: 25460505
顯示更多

收起更多
亞細胞定位：

Nucleus. Chromosome. Cytoplasm. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.
蛋白家族：

Protein kinase superfamily, CAMK Ser/Thr protein kinase family, NIM1 subfamily
組織特異性：

Expressed ubiquitously with the most abundant expression in thymus, testis, small intestine and colon.
數據庫鏈接：

HGNC: 1925

OMIM: 603078

KEGG: hsa:1111

STRING: 9606.ENSP00000388648

UniGene: Hs.24529

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human